XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 08, 2017
Jul. 06, 2017
Sep. 01, 2014
Jun. 23, 2018
Apr. 18, 2018
May 31, 2017
Oct. 25, 2016
Jun. 30, 2016
May 31, 2016
Dec. 31, 2015
Jan. 31, 2015
Sep. 30, 2014
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Jun. 21, 2016
Operating lease periodic payment                     $ 709                    
Frequency of periodic payment                     Monthly                    
Operating lease rental expense                         $ 2,147   $ 2,126   $ 4,251 $ 8,502 $ 4,960    
Operating lease expiration date                     May 31, 2017                    
Lease agreement description                     <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.</font></p>             <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.</font></p>      
Stock Purchase Agreement [Member]                                          
Business acquisition, description       <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The purchase price payable in cash is €700,000. Closing of the acquisition is subject to satisfactory completion of due diligence, delivery of audited and interim financial statements of Cosmofarm subject to being audited by PCAOB auditors, no material adverse change in the business or financial condition of Cosmofarm, all necessary consents and approvals to complete the acquisition have been obtained and other customary closing conditions. As of June 30 2017, Cosmofarm is undergoing an audit of the company’s financial statements for the last two years by a PCAOB audit firm, the SPA has not closed and Cosmos has not paid the €700,000.</font></p>                                  
Private Placement [Member]                                          
Commitments and contingencies description <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 8, 2017, the Company entered into an agreement with a third-party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.</font></p>                                        
Lease agreement description <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or May 16, 2018.</font></p>                                        
SkyPharm [Member]                                          
Operating lease periodic payment     $ 4,802     $ 1,250           $ 4,802                  
Frequency of periodic payment     Monthly     Monthly           Monthly                  
Operating lease rental expense                         $ 32,684   25,198 $ 65,367 50,397        
Term of operating lease     6 years                 6 years                  
Advisory agreement, description         <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.</font></p>                                
SkyPharm [Member] | Additional space [Member]                                          
Operating lease periodic payment               $ 2,021 $ 886                        
Frequency of periodic payment               Monthly Monthly                        
SkyPharm [Member] | First Floor [Member]                                          
Operating lease periodic payment                   $ 886                      
Frequency of periodic payment                   Monthly                      
CC Pharma GmbH [Member]                                          
Non-refundable fee                                         $ 454,800
Expense paid   $ 454,800                               $ 454,800 454,800    
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                          
Operating lease periodic payment                               $ 1,500   $ 1,500      
Common stock shares reserved                         200,000     200,000   200,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Preclinical Trials [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                          
Common stock shares reserved                         50,000     50,000   50,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | conclusion of Phase I testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                          
Common stock shares reserved                         50,000     50,000   50,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase II testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                          
Common stock shares reserved                         50,000     50,000       50,000  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase III testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                          
Common stock shares reserved                         50,000     50,000   50,000      
Amplerissimo [Member]                                          
Operating lease periodic payment                               $ 122   $ 124      
Frequency of periodic payment                               Monthly   Monthly      
Operating lease rental expense                         $ 399   $ 358 $ 799 715 $ 1,492 1,462    
Operating lease renewal date                               Jul. 31, 2018   Jul. 31, 2018      
Decahedron [Member]                                          
Operating lease periodic payment             $ 2,470                            
Operating lease rental expense                               $ 15,753 $ 12,076 $ 27,180      
Operating lease expiration date             Oct. 24, 2021                            
MediHelm S.A. [Member] | SkyPharm [Member]                                          
Operating lease periodic payment                               $ 8,758          
Frequency of periodic payment                               Monthly          
Operating lease rental expense                           $ 33,180   $ 24,891   $ 116,400 89,323    
Total monthly operating lease amount                                     $ 8,758